Chairman

We offer “NKT cell-targeted therapy” for cancer and autoimmune diseases, jointly developed by Chiba University Hospital and RIKEN.
This therapy artificially activates NKT cells, which serve as commanders of the immune system, to strongly restore both innate and adaptive immunity.
Although this is a cutting-edge treatment under clinical research worldwide, it is currently available only at a limited number of medical institutions in Japan.
More than 1,000 patients have already received this therapy, and there have been reported cases in which tumors have nearly disappeared.
Our attending physician, Chairman Shimada, has experience in cell therapy research at the Center for iPS Cell Research and Application (CiRA) of Kyoto University, and provides safe and effective treatment based on scientific evidence.